Context Therapeutics receives FDA fast track status for ovarian cancer drug

April 2, 2026 7:30 AM

Context Therapeutics Inc. (NASDAQ: CNTX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to CTIM-76 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found